<p><strong>公司与华侨银行签署了配售协议。</strong></p>
<p>iX Biopharma Ltd. 已获得新加坡交易所证券交易有限公司的原则性批准，允许其在拟议的配售中上市和报价最多 7580 万股新股。</p>
<p>根据 2 月 19 日的交易所公告，拟议的配售预计将筹集不少于 600 万美元的总收入。</p>
<p>配售协议是与华侨银行有限公司签署的。公司早前于 2 月 13 日公布了拟议配售的结果。</p>
<p>新加坡交易所的原则性批准需遵守交易所的上市要求，并不应被视为对拟议配售、公司、其子公司或其股票的优点的指示，公司表示。</p>
<p>拟议的配售仍需满足配售协议中规定的条件。</p>

IX生物制药

<p>iX 生物制药有限公司已获得新加坡交易所的批准，计划发行最多 7580 万股新股，预计筹集至少 600 万美元。该配售协议与华侨银行达成，批准的前提是满足交易所的上市要求。公司此前于 2 月 13 日公布了配售结果，批准并不表示对配售或公司股票的优劣</p>

<p><strong>The company entered a placement agreement with OCBC.</strong></p>
<div class="lb-trans"><p><strong>公司与华侨银行签署了配售协议。</strong></p>
</div><p>iX Biopharma Ltd. has received approval-in-principle from the Singapore Exchange Securities Trading Limited for the listing and quotation of up to 75.8 million new shares under its proposed placement.</p>
<div class="lb-trans"><p>iX Biopharma Ltd. 已获得新加坡交易所证券交易有限公司的原则性批准，允许其在拟议的配售中上市和报价最多 7580 万股新股。</p>
</div><p>The proposed placement is expected to raise gross proceeds of no less than $6m, according to a bourse filing dated 19 February.</p>
<div class="lb-trans"><p>根据 2 月 19 日的交易所公告，拟议的配售预计将筹集不少于 600 万美元的总收入。</p>
</div><p>The placement agreement was entered into with Oversea-Chinese Banking Corporation Limited. The company had earlier announced the results of the proposed placement on 13 February.</p>
<div class="lb-trans"><p>配售协议是与华侨银行有限公司签署的。公司早前于 2 月 13 日公布了拟议配售的结果。</p>
</div><p>The SGX-ST’s approval-in-principle is subject to compliance with the exchange’s listing requirements and is not to be taken as an indication of the merits of the proposed placement, the company, its subsidiaries or its shares, the company said.</p>
<div class="lb-trans"><p>新加坡交易所的原则性批准需遵守交易所的上市要求，并不应被视为对拟议配售、公司、其子公司或其股票的优点的指示，公司表示。</p>
</div><p>The proposed placement remains subject to the fulfilment of conditions set out in the placement agreement.</p>
<div class="lb-trans"><p>拟议的配售仍需满足配售协议中规定的条件。</p>
</div>

IX 生物制药获得新加坡交易所的批准，以 600 万美元的配售方式发行 7580 万股